J
Joshua A. Horwitz
Researcher at Rockefeller University
Publications - 36
Citations - 4370
Joshua A. Horwitz is an academic researcher from Rockefeller University. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 22, co-authored 34 publications receiving 3810 citations. Previous affiliations of Joshua A. Horwitz include Cornell University & Harvard University.
Papers
More filters
Journal ArticleDOI
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey,Florian Klein,Julio C. C. Lorenzi,Michael S. Seaman,Anthony P. West,Noreen Buckley,Gisela Kremer,Lilian Nogueira,Malte Braunschweig,Johannes F. Scheid,Joshua A. Horwitz,Irina Shimeliovich,Sivan Ben-Avraham,Maggi Witmer-Pack,Martin Platten,Clara Lehmann,Leah A. Burke,Thomas Hawthorne,Robert J. Gorelick,Bruce D. Walker,Tibor Keler,Roy M. Gulick,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig +24 more
TL;DR: It is concluded that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV- 1 prevention, therapy and cure.
Journal ArticleDOI
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Florian Klein,Ariel Halper-Stromberg,Joshua A. Horwitz,Henning Gruell,Henning Gruell,Johannes F. Scheid,Johannes F. Scheid,Stylianos Bournazos,Hugo Mouquet,Linda Spatz,Linda Spatz,Ron Diskin,Alexander Abadir,Trinity Zang,Marcus Dorner,Eva Billerbeck,Rachael N. Labitt,Christian Gaebler,Christian Gaebler,Paola Marcovecchio,Reha Baris Incesu,Thomas Eisenreich,Paul D. Bieniasz,Paul D. Bieniasz,Michael S. Seaman,Pamela J. Bjorkman,Jeffrey V. Ravetch,Alexander Ploss,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
TL;DR: Combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV- 1-infected individuals.
Journal ArticleDOI
A genetically humanized mouse model for hepatitis C virus infection
Marcus Dorner,Joshua A. Horwitz,Justin B. Robbins,Walter T. Barry,Qian Feng,Kathy Mu,Christopher T. Jones,John W. Schoggins,Maria Teresa Catanese,Dennis R. Burton,Dennis R. Burton,Mansun Law,Charles M. Rice,Alexander Ploss +13 more
TL;DR: It is demonstrated that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge.
Journal ArticleDOI
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid,Johannes F. Scheid,Joshua A. Horwitz,Yotam Bar-On,Edward F. Kreider,Ching-Lan Lu,Julio C. C. Lorenzi,Anna Feldmann,Malte Braunschweig,Lilian Nogueira,Thiago Y. Oliveira,Irina Shimeliovich,Roshni Patel,Leah A. Burke,Yehuda Z. Cohen,Sonya Hadrigan,Allison Settler,Maggi Witmer-Pack,Anthony P. West,Boris Juelg,Tibor Keler,Thomas Hawthorne,Barry S. Zingman,Roy M. Gulick,Nico Pfeifer,Gerald H. Learn,Michael S. Seaman,Pamela J. Bjorkman,Florian Klein,Florian Klein,Florian Klein,Sarah J. Schlesinger,Bruce D. Walker,Bruce D. Walker,Beatrice H. Hahn,Michel C. Nussenzweig,Marina Caskey +36 more
TL;DR: It is concluded that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans, suggesting failure to escape over a period of 9-19 weeks.
Journal ArticleDOI
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
Ariel Halper-Stromberg,Ching-Lan Lu,Florian Klein,Joshua A. Horwitz,Stylianos Bournazos,Lillian Nogueira,Thomas Eisenreich,Cassie Liu,Anna Gazumyan,Uwe Schaefer,Rebecca C. Furze,Michael S. Seaman,Rab K. Prinjha,Alexander Tarakhovsky,Jeffrey V. Ravetch,Michel C. Nussenzweig,Michel C. Nussenzweig +16 more
TL;DR: It is shown that broadly neutralizing antibodies (bNAbs) can interfere with establishment of a silent reservoir by Fc-FcR-mediated mechanisms, and combinations of inducers and bNAbs constitute a therapeutic strategy that impacts the establishment and maintenance of the HIV-1 reservoir in humanized mice.